Halozyme Therapeutics, Inc. (HALO) · Aug 6, 2026 · Company update

Royalty strength drives a major earnings beat and broad guidance raise

Royalty strength drives a major earnings beat and broad guidance raise

The quarter cleared expectations by a wide margin. Against a published pre-release estimate of roughly $405 million in revenue and $1.80 in adjusted EPS, Halozyme delivered $481.0 million and $2.28, respectively — approximately 19% and 27% above those benchmarks.

MetricQ2 2026Q2 2025Year-over-year / expectation
Total revenue$481.0M$325.7M+48%; versus ~$405M published estimate
Royalty revenue$307.7M$205.6M+50%
GAAP diluted EPS$1.90$1.33+43%
Non-GAAP diluted EPS$2.28$1.54+48%; versus ~$1.80 published estimate
Adjusted EBITDA$328.8M$225.5M+46%
Cash, cash equivalents, restricted cash and marketable securities$231.9M$145.4M at Dec. 31, 2025Increased despite buybacks

Royalty growth, not a one-off collaboration payment, powered the upside. Royalties rose to $307.7 million, led by continued uptake of partner products including VYVGART Hytrulo and DARZALEX SC, while product sales increased to $129.6 million from $81.5 million. Collaboration revenue was only $43.7 million, so the beat reflects stronger recurring commercial royalties and product sales rather than reliance on a single deal payment (Income Statement; Financial Highlights).

Management raised every major 2026 target, materially resetting the earnings bar. The midpoint increased about 6% for total revenue, 7% for royalty revenue, 8% for adjusted EBITDA and 10% for non-GAAP EPS. That is a meaningful upgrade from the prior outlook, particularly because royalty revenue — the most strategically important and recurring component — now carries a $1.220 billion to $1.245 billion forecast versus $1.130 billion to $1.170 billion previously (2026 Guidance table).

The pipeline and capital-return updates add support, but are not all new information. The Vertex, Oruka, GSK and Incyte collaborations were announced earlier in 2026, so their inclusion mainly reinforces the expanding opportunity set rather than representing fresh quarter-end upside. The $332.8 million Q2 repurchase was substantial and reduced weighted-average diluted shares to 121.2 million from 124.2 million a year earlier, while cash and marketable securities still increased to $231.9 million (Corporate Activities; Balance Sheet; EPS Reconciliation).

Net read: a broad, substantive positive surprise. The filing combines a large revenue and adjusted-EPS beat with stronger-than-expected royalty momentum and a full-year guidance raise across all key measures. Higher amortization, R&D and SG&A from the Elektrofi and Surf Bio acquisitions and $6.9 million of patent-litigation costs temper reported margins, but they do not outweigh the recurring-revenue upside (Income Statement; Adjusted EBITDA Reconciliation).

Original filing on SEC EDGAR

More Halozyme Therapeutics, Inc. news

Royalty strength drives a major earnings beat and broad guidance raise | HALO Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.